COMMUNIQUÉS West-GlobeNewswire

Good Supply Cannabis Introduces New Signature ‘Bud Squad’ Products

24/04/2024 - 13:00

TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company today announced the release of new cannabis flower [...]

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

24/04/2024 - 13:00

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with [...]

ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference

24/04/2024 - 13:00

SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the [...]

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology

24/04/2024 - 10:05

The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster [...]

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

24/04/2024 - 10:00

The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi ® and Simponi Aria ® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritis Alvotech [...]

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

24/04/2024 - 10:00

The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria ® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritis Alvotech [...]

Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair

24/04/2024 - 09:00

Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next [...]

AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting

24/04/2024 - 08:00

MILAN, Italy, April 24, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for [...]

Pharming Group to report first quarter 2024 financial results on May 8

24/04/2024 - 08:00

Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period [...]

Vistin Pharma ASA: First quarter 2024 financial results

24/04/2024 - 07:44

Oslo, Norway, 24 th of April 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024. Revenue in the first quarter ended at MNOK 104 compared to MNOK 101 in Q1 2023. Sales [...]

Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent

24/04/2024 - 07:30

Press Release Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent April 24, 2024 – release at 07:30 CET Sophia Antipolis, France Nicox SA ( [...]

Nicox : Deuxième convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 6 mai 2024 et désignation d’un mandataire ad hoc

24/04/2024 - 07:30

Communiqué de presse Nicox : Deuxième convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 6 mai 2024 et désignation d’un mandataire ad hoc 24 avril 2024 – diffusion à 07h30 Sophia Antipolis, France Nicox [...]

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

24/04/2024 - 07:00

Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, [...]

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

24/04/2024 - 07:00

PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.     Q1 2024   Q1 2023   % change   €m   €m   [...]

Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024

24/04/2024 - 07:00

PARIS, FRANCE, 24 avril 2024 - Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de spécialité, publie aujourd’hui son chiffre d’affaires pour le premier trimestre 2024. Q1 2024 Q1 2023 % change €m [...]

BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023

24/04/2024 - 07:00

PRESS RELEASE - PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of [...]

BioSenic reporte son assemblée générale annuelle des actionnaires et fournit des chiffres financiers temporaires non-audités pour 2023

24/04/2024 - 07:00

COMMUNIQUE DE PRESSE – INFORMATION PRIVILIGIEE Compte tenu du plan de restructuration annoncé le 11 avril 2024, BioSenic a décidé de reporter la publication de son rapport annuel 2023 ainsi que son assemblée générale [...]

Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates

24/04/2024 - 07:00

Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory [...]

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

24/04/2024 - 07:00

Group sales grew by 2% 1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there [...]